Stemline Therapeutics: 4Q Earnings Snapshot
NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Friday reported a loss of $17.7 million in its fourth quarter.
On a per-share basis, the New York-based company said it had a loss of 38 cents.
The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 39 cents per share.
The biopharmaceutical company posted revenue of $11.8 million in the period, meeting Street forecasts.
For the year, the company reported that its loss narrowed to $76.8 million, or $1.83 per share. Revenue was reported as $43.2 million.
In the final minutes of trading on Friday, the company’s shares hit $4.53. A year ago, they were trading at $13.51.